Skribe Medical Discloses $1.65M for Cardiac Wearables

The extra appointment arrives inside a course of cancer treatment that already asks a great deal of the patient. Skribe Medical is developing a wearable cardiac assessment intended to bring some of that work into the oncology visit, where the person receiving treatment and the team responsible for it are already together.

The US medical technology company disclosed $1.65M in pre-seed backing in a November 11, 2026 development update, naming SeaX Ventures as lead investor alongside GoAhead Ventures and Marin Sonoma Impact Ventures. The capital has supported technology development and clinical research. Skribe's Aurora System estimates left ventricular ejection fraction, a measure of cardiac pumping function, and is undergoing clinical evaluation.

Skribe's current progress connects an early financing to the practical work of generating medical evidence. Its founders are pursuing a more convenient assessment, while clinicians still need reliable information about a patient's heart before deciding how to manage care.

What Skribe's funding disclosure establishes

The financing history needs a calendar attached. Skribe announced a closed pre-seed round on September 2, 2025, naming GoAhead Ventures, Marin Sonoma Impact Ventures and angel investors. That announcement supplied no amount, and the November 2026 release describes existing $1.65M backing without giving a new close date.

A June 2026 interview with CEO Ryan Neely also discussed an earlier pre-seed round. The available evidence supports reporting the disclosed backing and its role in development, while leaving the original financing date and any relationship between separate announcements unresolved. Adding the amounts together would manufacture a larger capital history than the sources establish.

That distinction changes the investment story. The useful question is how the early capital has accompanied a device moving through clinical development. A later company update can reveal more about an existing investment without turning the date on the release into the date money arrived.

For operators evaluating a medical technology company, that chronology helps connect the financing with the work it funded. Skribe's announcement now offers a view into research activity and an investor's hospital relationships, rather than a newly verified cash injection or a disclosed commercialization timetable.

Bringing a cardiac measurement into cancer care

Skribe's current product description starts with a workflow: assess cardiac function in minutes during cancer care. Some cancer therapies can damage the heart, creating a need to monitor function alongside treatment. An assessment that requires another visit introduces scheduling and coordination around a patient who is already navigating a demanding course of care.

Aurora combines measurements from an adhesive patch with AI-based analysis. The FDA's READI-Home listing describes electrocardiography, phonocardiography and seismocardiography as inputs for estimating left ventricular ejection fraction. In the proposed home-use configuration, results would reach a healthcare professional for interpretation.

The clinical comparison matters as much as the convenience. Skribe's NOECHO study evaluates its wearable measurements against echocardiography, the ultrasound examination used to assess cardiac function. A patch that is simpler to place still needs evidence appropriate to the clinical decisions its readings might inform. Ease of use gives the development program a practical purpose; the comparison study addresses whether those measurements can support that purpose.

The company reports more than 800 participants across 10 US sites and an additional Southeast Asian site. That is a measure of research enrollment, with performance outcomes still to be established in the evidence reviewed here. The immediate commercial relevance lies in the care setting Skribe wants to serve: an oncology team looking for useful cardiac information during an appointment already on the calendar.

Founders and investors working around the study

Skribe's leadership team includes co-founder and CEO Ryan Neely, Ph.D.; co-founder and CTO Josh Kay; and co-founder and CSO Andrew Bohannon, Ph.D. The founders previously worked together at iota Biosciences, according to the company. Their current roles combine the scientific, technical and company-building work involved in moving a sensing system toward clinical use.

Neely's Key Tech interview describes an early development process built around rapid prototypes and access to clinical data. For a small medical-device team, the sequence is consequential: a prototype gives the founders something to measure, and the measurements help determine what deserves more development. The interview also shows why the setting matters. Neely described a clinic device intended for a nurse or medical assistant to use before the physician arrives.

SeaX's contribution extends into the research relationships. Skribe's November update says the investor connected the company with hospital partners in Southeast Asia and supported recruitment of more than 100 study participants. Those patients should not be added to the broader enrollment count as a separate commercial metric. The point is that an investor's network can take on an operating role inside the company's development program.

For a founder, a useful introduction depends on what the person at the other end can help accomplish. Here, the relationship reaches a hospital and a study population. That gives the financing a second dimension: access to settings where the technology can be examined, with different patients and clinical teams contributing to the body of evidence.

The path from research visits toward home use

Aurora's selection for the FDA READI-Home Innovation Challenge creates an opportunity for regulatory engagement around home-use development. The agency explicitly states that selection confers no marketing authorization and guarantees no future regulatory outcome. Skribe's nearer-term clinic ambition and longer-term home-monitoring goal therefore belong at different points in the development story.

Moving assessment closer to the patient also moves responsibility through the care workflow. A clinician still has to interpret a result and decide whether it changes the next step. That relationship is visible in the FDA's device description, which keeps the healthcare professional at the receiving end of the proposed home system.

Skribe has not supplied a verified commercial launch date, reimbursement pathway or clinical performance result in the sources reviewed for this article. Its disclosed backing is supporting a development program whose practical destination is easier to picture than its eventual purchasing model. An oncology team would need to understand how the assessment fits the visit, what evidence supports the reading and how that information reaches the person making the treatment decision.

For Neely, Kay and Bohannon, the work continues through those encounters between a sensor, a patient and a clinical team. Each study visit gives Skribe another opportunity to examine whether cardiac assessment can occupy a smaller part of a cancer patient's day while giving the treating team information it can use.